Lumibird Medical, a global leader in ophthalmic medical devices, has announced the rebranding of its Japanese subsidiary. Formerly known as Ellex Japan, the company will now operate under the name Lumibird Medical Japan, effective January 6, 2025.
The subsidiary, established in Osaka in 2003, relocated its headquarters to Tokyo in 2015 to better serve the Japanese ophthalmology market. This rebranding marks a new chapter in the company’s growth, emphasizing Lumibird Medical’s commitment to delivering innovative solutions and transformative patient outcomes in ophthalmology.
“We have seen remarkable growth in the ophthalmic laser market,” said John Hsieh, president and representative director of Lumibird Medical Japan, in a news release. “We are eager to expand further by introducing advanced ophthalmic ultrasound equipment and, as we look to the future, groundbreaking solutions for dry eye treatment. This rebranding represents our dedication to these opportunities for our customers, partners and stakeholders; thanks to the same trusted team and exceptional support.”
Lumibird Medical CEO Jean-Mark Gendre added, “This rebranding underscores our ambitions to strengthen our position in the ophthalmology sector in Japan and to bring cutting-edge solutions to our customers more efficiently.”
Lumibird Medical, the medical division of the Lumibird Group, provides healthcare professionals worldwide with innovative diagnostic and treatment solutions, focusing on laser and ultrasound technologies. The group’s offerings target the leading causes of blindness—cataract, glaucoma, diabetic retinopathy and macular degeneration—as well as other conditions such as dry eye.
Lumibird Medical Japan will debut its new name at the 129th Annual Meeting of the Japanese Ophthalmological Society in Tokyo, scheduled for April 17-20, 2025. At the event, attendees will have the opportunity to explore the company’s full range of ophthalmic laser and ultrasound equipment and participate in educational seminars on glaucoma laser therapy.
